We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Amla (Indian Gooseberry)
An antioxidant- and vitamin-C-rich fruit (Emblica officinalis) with several small-to-moderate RCTs showing modest improvements in lipid profile, fasting glucose, and endothelial function — but the trials are mostly short, India-based, and use proprietary extracts, and at least one rigorous double-blind RCT found no benefit. Promising but emerging.
What the evidence says
Most Amla studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2014–2026 with a typical study size of 40 participants.
Based on 25 studies · 2 meta-analyses · 12 RCTs · 40 total participants
Confidence
High confidenceBy outcome
A 5-RCT meta-analysis and small double-blind trials show lower cholesterol, glucose, and CRP, but the trials are small, short, single-center Indian extracts and one rigorous 150-patient RCT found no benefit.
17 rigorous studies
13 randomized trials · 2 meta-analyses · 4 systematic reviews
Our evidence rating for Amla is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
1 trial ongoing or recruiting · 16 completed on ClinicalTrials.gov
Registered trials show research momentum for Amla, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Under EU law (Reg. 1924/2006), EFSA reviews whether a specific health claim for Amla meets the evidence standard. These are independent regulatory decisions on claims — not studies, and never counted toward the evidence score above.
Not authorised by EFSA
“Emblica officinalis FRUIT RIND Supports eye function”
“Emblica officinalis FRUIT RIND Gives strength and energy. Helps build muscle”
“Emblica officinalis FRUIT RIND Supports the reproductive and urinary systems”
“Emblica officinalis (Indian Gooseberry) Softens the mucous membrane of throat”
“Emblica officinalis FRUIT RIND Has a gentle cleansing action. Helps neutralise toxins”
“Emblica officinalis (common name : Amla) -Helps to promote healthy ageing -Helps to protect from oxidative cell /DNA damage”
“Emblica officinalis FRUIT RIND Supports the digestion and metabolism of sugars. Helps to maintain normal blood glucose level”
“Not authorised” means the specific claim wording did not meet the EU’s evidence standard — often a matter of dossier or phrasing, not proof of no effect. EFSA judges marketing claims and is kept separate from our study-based evidence score.
Source: EU Register of nutrition and health claims (European Commission / EFSA) · register snapshot Feb 2013
Amla (Indian gooseberry, Emblica officinalis / Phyllanthus emblica) is a fruit used for centuries in Ayurvedic medicine and rich in vitamin C, tannins, and polyphenols. Its proposed cardiometabolic benefits rest on antioxidant and anti-inflammatory activity.
The human evidence is genuinely mixed-but-leaning-positive: a 2023 meta-analysis of five RCTs found significant reductions in total cholesterol, LDL, triglycerides, fasting glucose, and CRP, plus a rise in HDL.
Individual double-blind, placebo-controlled RCTs in dyslipidemia and metabolic syndrome reported improvements in lipids, endothelial function, oxidative-stress markers, and inflammation.
However, the trials are mostly small (40-150 participants), short (3-12 weeks), conducted at single Indian centers, and use standardized proprietary extracts — and a well-conducted 150-patient double-blind RCT in hypertension found NO benefit on blood pressure, lipids, or inflammation.
So amla is a plausible adjunct for lipids and glycemic control, but the evidence base is still emerging rather than definitive.
High vitamin-C and polyphenol content raises nitric oxide and glutathione and lowers malondialdehyde, reducing oxidative stress.
Lowers total cholesterol, LDL, and triglycerides while raising HDL in several trials, without depleting CoQ10 the way statins do.
Reduces high-sensitivity CRP, a systemic inflammation marker, in dyslipidemic and metabolic-syndrome subjects.
How Amla works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Monitor blood glucose for additive lowering effects.
Not adequately studied — use caution or avoid.
May add to glucose-lowering effects — monitor blood sugar if combined with insulin or oral hypoglycemics.
High vitamin-C and polyphenol content could theoretically affect bleeding risk; clinical relevance is low but caution is reasonable around surgery.
Tip: Take with food
Amla has an evidence score of 4.8/10 — emerging evidence based on 18 indexed studies, including 1 meta-analysis. An antioxidant- and vitamin-C-rich fruit (Emblica officinalis) with several small-to-moderate RCTs showing modest improvements in lipid profile, fasting glucose, and endothelial function — but the trials are mostly short, India-based, and use proprietary extracts, and at least one rigorous double-blind RCT found no benefit. Promising but emerging. Representative study: PMID 36934568.
The commonly studied dose of Amla is 500 mg standardized extract twice daily (1 g/day) in most positive trials. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Amla is with meals. Take it with food. Trials dosed standardized extract twice daily with meals over 12 weeks.
Amla is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects are uncommon and include mild GI upset. Use caution if any of these apply to you: Pregnancy/breastfeeding (not adequately studied).
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Alpha Lipoic Acid
Likely helpsUniversal antioxidant that works in both water and fat, supporting blood sugar control, nerve health, and cellular energy.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 25 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research